Changes in amyloid-beta-oligomer (AβΟ) peptides levels are considered one of the major neuropathologic biomarkers for Alzheimer's Disease (AD). AβΟ levels can be detected using a variety of techniques such as neuroimaging, single molecule detection, immunoassays, and polymerase chain reaction (PCR). However, such techniques are usually reserved for individuals with mild cognitive decline or symptoms of late onset AD often to the exclusion of those with subjective memory complaints and patients in the early presymptomatic stages of AD. Recently, many scientists have sought to address this issue by integrating these techniques onto a single device or inexpensive platform permitting routine measurements of AβΟ concentrations outside the clinic. In this review, we examine the different types of clinical AβΟ commercial assays and established analytical techniques currently employed in the diagnosis of AD as well as integrated optical and electrochemical sensing devices currently under development.

淀粉样β-寡聚物（Aβ0）肽水平的变化被认为是阿尔茨海默氏病（AD）的主要神经病理生物标记之一。可以使用多种技术来检测Aβ0水平，例如神经成像，单分子检测，免疫测定和聚合酶链反应（PCR）。但是，此类技术通常保留给具有轻度认知功能减退或AD发作较晚的症状的患者，通常将那些主观记忆障碍的患者和AD症状早期的患者排除在外。最近，许多科学家试图通过将这些技术集成到单个设备或廉价的平台上以允许在诊所外常规测量AβO的浓度来解决这个问题。在这篇评论中